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Although negative selection in the thymus and induction
of anergy in the periphery have been widely accepted as
mechanisms for controlling autoreactivity, much less atten-
tion has been devoted to the role of suppressor T cells in
mediating dominant immunologic self-tolerance. In 1995,
Sakaguchi et al. (1, 2) made the seminal observation that the
 
transfer of CD4
 
 
 
 T cells which had been depleted of the
 
minor subpopulation (10%) of cells that coexpressed the IL-2
 
receptor (IL-2R) 
 
 
 
-chain (CD25) to nu/nu recipients in-
 
duced organ-specific autoimmune disease in the majority
of recipients. Cotransfer of CD4
 
 
 
CD25
 
 
 
 cells with the
CD4
 
 
 
CD25
 
 
 
 cells prevented the development of disease.
The CD4
 
 
 
CD25
 
 
 
 population was also shown to be solely
responsible for the prevention of autoimmunity observed
after mice are thymectomized on the third day of life (3).
 
Rapid progress in the analysis of the regulatory function
 
of the CD4
 
 
 
CD25
 
 
 
 T cell population was made by the
development of in vitro model systems that mimicked the
function of these cells in vivo (4–6). Although minor dif-
ferences were observed in the results obtained by the dif-
ferent groups, it is widely accepted that these cells are both
hyporesponsive and suppressive. Further studies demon-
strated that the CD4
 
 
 
CD25
 
 
 
 T cells act through an APC-
 
independent mechanism (7, and
 
 
 
unpublished observations).
Induction of suppressor activity requires that the CD4
 
 
 
CD25
 
 
 
 cells be activated through their TCR, but once ac-
tivated, they suppress T cell activation in an antigen-inde-
pendent manner without a requirement for reactivation
 
through their TCR. Therefore, we proposed (4) that CD4
 
 
 
CD25
 
 
 
 cells represent a unique lineage of CD4
 
 
 
 T cells
that function as “professional suppressor cells.” The publi-
cation in this issue of four papers dealing with different as-
pects of the function of CD4
 
 
 
CD25
 
 
 
 T cells clearly indi-
cates that they have now received their “professional
certification.”
 
CD4
 
 
 
CD25
 
 
 
 T Cells Are Generated in the Thymus.
 
Saoudi et al. (8) were the first to describe that potent T
regulatory (Tr) cells were present in the thymus of the
adult rat. PVG rats develop autoimmune diabetes after
adult thymectomy and split-dose irradiation. Transfer of
 
CD4
 
 
 
CD8
 
 
 
 
 
thymocytes or CD4
 
 
 
CD45RC
 
 
 
 peripheral T
cells prevented the development of disease. Subsequently,
CD4
 
 
 
CD25
 
 
 
 T cells were identified in the mouse thymus
(9) and shown by Itoh et al. (10) to resemble peripheral
CD4
 
 
 
CD25
 
 
 
 T cells in their in vivo and in vitro suppres-
sive capacities. Stephens and Mason (11) recently demon-
strated that CD25 is also a marker for the CD4
 
  
 
T cells in
the rat thymus that prevent autoimmune diabetes.
As the expression of CD25 appears during the transition
of the CD4
 
 
 
CD8
 
 
 
 T cell to the CD4
 
 
 
CD8
 
 
 
 T cell (9),
the generation of CD4
 
 
 
CD25
 
 
 
 T cells is part of normal
thymocyte differentiation. We have proposed that (12) the
induction of expression of CD25 (and perhaps other T cell
activation antigens) reflects activation of this cell during a
process that we have termed “altered negative selection.”
CD4
 
 
 
 T cells that develop into CD25
 
 
 
 T cells are likely to
express a TCR with an intermediate affinity for self. This
affinity is too low for negative selection, yet too high to al-
low the T cells to pass through to the periphery. As a result
of this process of activation in the thymus, CD4
 
 
 
CD25
 
 
 
 T
cells are rendered nonresponsive and suppressive.
Jordan et al. (13) have recently validated this hypothesis
by demonstrating that T cells in mice expressing a high af-
finity transgenic TCR for influenza hemagglutinin (HA) as
well as an HA peptide (under the control of SV40 early re-
gion promoter-enhancer sequences) developed into func-
tional CD4
 
 
 
CD25
 
 
 
 suppressor cells. Radioresistant ele-
ments of the thymus played a critical role in generating the
CD4
 
 
 
CD25
 
 
 
 T cells. In contrast, mice expressing an anti-
HA TCR of much lower affinity did not develop into
CD25
 
 
 
 T cells. The authors of this study propose that
CD25
 
  
 
T cells must express a TCR with a high affinity for
the selecting peptide in order to be subsequently highly re-
active with self-peptides they would encounter in the pe-
riphery. Although this double transgenic model offers a
major insight into the mechanism of generation of the
CD25
 
 
 
 lineage, these experiments should be interpreted
with caution as the self-antigen under study was widely ex-
pressed not only on all elements in the thymus, but in the
periphery as well. The normal selection of CD25
 
 
 
 T cells
may involve other cellular elements in the thymus, such as
bone marrow–derived dendritic cells (DCs), and may yield
CD25
 
 
 
 T cells expressing a broader spectrum of affinities.
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Identification of CD4
 
 
 
CD25
 
 
 
 T Cells in Man.
 
Three
papers in this issue (14–16) and three papers (17–19) ap-
pearing elsewhere now describe the properties of human
CD4
 
 
 
CD25
 
 
 
 T cells. Given the obsession of most cellular
immunologists with the concept of separating functionally
distinct populations of cells based on their differential ex-
pression of membrane antigens, it is surprising that 6 yr
elapsed between the identification of these cells in the
mouse and the confirmation of their existence in man. One
wonders if the human/clinical immunologists remained
wary of the possible existence of “suppressor cells” based
on the failure of biochemical and molecular studies to con-
firm their existence in the mouse in the early 1980’s. In any
case, there is marked agreement about the properties of hu-
man CD4
 
 
 
CD25
 
 
 
 T cells and it is somewhat reassuring
that they resemble their murine counterpart in almost all of
their critical properties.
Although most of these papers report that 5–15% of hu-
man CD4
 
 
 
 T cells coexpress CD25, the sharp distinction
observed between murine CD25
 
  
 
and CD25
 
 
 
 T cells with
the available mAbs and flow cytometry is not as evident in
the human studies. Human CD25
 
 
 
 T cells also have the
phenotype of activated/memory T cells in that they are
predominantly CD45RO
 
 
 
 and a variable number also ex-
press MHC class II antigens. In one study (18), they were
also shown to be CD45RO
 
  
 
and CD45RB
 
low
 
 which is
consistent with T cells which have been restimulated by
antigen multiple times. The expression of CD122 (IL-2R
 
 
 
-chain) was easily detectable on human CD25
 
 
 
 T cells,
while its expression on murine CD25
 
 
 
 cells is controver-
sial. It is also notable that the frequency of CD4
 
 
 
CD25
 
 
 
Tr cells is equivalent in the thymus of humans, rats, and
mice (17). Thus, there appears to be remarkable evolution-
ary conservation across species in terms of the phenotype of
the cell population responsible for T cell suppression in
vivo. On the other hand, it is somewhat disappointing that
none of these papers attempts a more detailed evaluation of
the expression of some of the 260 CD markers now de-
fined on human leukocytes, since CD25 is an imperfect
marker that is expressed on every activated T cell. In view
of the availability of multiple Abs to human chemokine re-
ceptors, an evaluation of their differential expression on
human CD25
 
 
 
 and CD25
 
 
 
 T cells might have offered in-
sights as to how these cells are mobilized to sites of inflam-
mation.
All of the functional studies carried out with human
CD25
 
 
 
 T cells confirm what has been described with mu-
rine T cells. They are hyporesponsive to stimulation with
anti-CD3, combinations of anti-CD3 and anti-CD28,
and mature allogeneic DCs (mDCs). Alloantigen-activated
CD25
 
  
 
T cells exhibited a cell cycle arrest in the G
 
1
 
/G
 
0
 
phase. Human CD25
 
 
 
 cells respond to TCR stimulation
combined with IL-2, IL-4, and IL-15 although, even under
these conditions, their proliferative responses do not ap-
proach those of similarly stimulated CD25
 
 
 
 T cells.
CD25
 
 
 
 T cells were capable of suppressing the responses of
CD25
 
 
 
 cells to stimulation with anti-CD3 or alloantigen
(14–16) presented by mDCs. Once activated, their sup-
pressor function is nonspecific as was shown in studies of
murine CD25
 
 
 
 T cells (7). There is some variation among
the reports as to the capacity of human CD25
 
 
 
 T cells to
produce either effector or suppressor cytokines. This may
be secondary to the purity of the CD25
 
 
 
 cells used in the
assay and the specific assay (protein or mRNA). As has
been reported with murine CD25
 
 
 
 T cells (4, 6), human
CD25
 
 
 
 T cells appear to be capable of producing low lev-
els of IL-10 and perhaps TGF-
 
 
 
, although equivalent levels
of TGF-
 
 
 
 mRNA were also detectable in stimulated
CD25
 
  
 
T cells (16). Suppression in cocultures of CD25
 
 
 
/
CD25
 
 
 
 T cells could be abrogated to some extent by the
addition of IL-2, IL-4, or IL-15, alone or in combination.
The extent of reconstitution of proliferation was not as
complete as what has been observed in the mouse studies.
All of the papers agree that suppression cannot be over-
come by the addition of neutralizing Abs to IL-4, IL-10,
IL-10R, or TGF-
 
 
 
.
As has been observed with murine CD25
 
 
 
 T cells, all
studies demonstrate that human CD4
 
 
 
CD25
 
 
 
 T cells ex-
press intracellular cytotoxic T lymphocyte–associated anti-
gen (CTLA)-4 and expression is elevated after activation
and culture. It is widely accepted that binding of CTLA-4
by its ligands results in a downregulation of T cell activa-
tion. However, it remains possible that this interaction
might also lead to activation of certain T cell functions.
The high level of expression of CTLA-4 on CD25
 
 
 
 cells
continues to remain an enigma. Different laboratories have
reported disparate results. Takahashi et al. (20) claimed that
the addition of anti–CTLA-4 or its F(ab
 
 
 
) fragment would
reverse suppression in cocultures of murine CD25
 
 
 
/
CD25
 
 
 
 cells. We have been unable to confirm these find-
ings and have recently shown that induction of CD25
 
 
 
-
mediated suppressor function appears to be independent of
costimulatory signals mediated by the interaction of either
CD28 or CTLA-4 with their ligands, CD80/CD86 (un-
published observations). All of the human studies (14–19)
fail to demonstrate reversal of suppression when anti–
CTLA-4 or its F(ab
 
 
 
) fragment (19) is added. Nevertheless,
the in vivo studies of both Takahashi et al. (20) and Read
et al. (21) strongly implicate a role for CTLA-4 at some
stage in the induction of CD25
 
 
 
-mediated suppressor
function during the pathogenesis of autoimmunity. One
possibility is that, under some circumstances, engagement
of CTLA-4 by its physiologic ligands or by Ab results in an
inhibition of the TCR-derived signals needed for induc-
tion of suppressor function and the failure of the CD25
 
 
 
 T
cells to inhibit the development of autoimmune disease.
This model is consistent with the accepted role of CTLA-4
in downregulating TCR-mediated activation of CD4
 
 
 
CD25
 
 
 
 T cells.
 
Mechanism of Suppression.
 
Taken together, all in vitro
studies of murine and human CD25
 
 
 
 T cells support a cell
contact–dependent, cytokine-independent mechanism of
suppression. Since suppression requires activation of the
CD25
 
 
 
 cells, it has been hypothesized that activation of
these cells via their TCR induces a cell surface molecule(s)
that mediates suppression by binding to a counter receptor 
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on the responder. The purported receptor on the CD25
 
 
 
T cell would also likely require induction by TCR-
induced activation. Candidate receptors might include
members of the TNFR superfamily or any cell surface anti-
gen that expresses an intracellular immunoreceptor tyro-
sine–based inhibitory motif.
In contrast to the lack of involvement of cytokines in
CD25
 
 
 
-mediated suppression in vitro, IL-10, IL-4, and
TGF-
 
 
 
 have been implicated as mediating suppression of
some (22–24), but not all (25, and unpublished observa-
tions), autoimmune diseases by Tr cells. While IL-10 is
produced by the Tr cells (24), it has not yet been shown
that IL-4 or TGF-
 
 
 
 are actually produced by CD25
 
 
 
 
 
regu-
latory cells in vivo. Thus, it is difficult to conclude if these
cytokines are responsible for the suppressive effects of the
Tr cells or if they play a role in the differentiation of the Tr
cells. Acceptance of a role for TGF-
 
 
 
 or IL-4 as mediators
of CD25
 
 
 
-mediated suppression will require an analysis of
the suppressive capacity of CD25
 
 
 
 T cells from TGF- /
IL-4–deficient mice, as well as an analysis of the suppress-
ability of CD25  T cells from mice which have genetic de-
fects in their capacity to respond to these cytokines. It will
also be important to determine if suppressive cytokines are
only produced by a subpopulation of the Tr cells.
CD4 CD25  T Cells and Transplantation Tolerance. Al-
most all in vivo studies of CD4 CD25  T cells have fo-
cused on their role in preventing organ-specific autoim-
mune diseases. As the studies on the human CD25  T cells
indicate that they are efficient suppressors of the mixed leu-
kocyte reaction (MLR) in response to alloantigen pre-
sented by mDCs, it seems likely that they may also play a
protective role in downregulating immune responses to al-
loantigen and preventing graft rejection. The paper by
Taylor et al. (26) in this issue, a complementary paper from
Hara et al. (27) in a recent issue of the Journal of Immunol-
ogy, and an earlier paper by Jonuleit et al. (28) strongly
support this view. Although these papers explore the role
of Tr cells in three very different experimental models, I
will attempt to point out the common threads in all three
studies and offer a unified explanation for all the experi-
mental results.
Taylor et al. (26, 29) have developed an in vitro model
for the induction of transplantation tolerance by culturing
C57BL/6 CD4  T cells with MHC class II incompatible
bm12 stimulators in the presence of anti-CD40L or anti-
CD80/CD86. After 10 d of culture, the recovered cells
from the anti-CD40 ligand (CD40L)– or anti-CD80/
CD86–treated cultures were poorly responsive upon in
vitro stimulation and most importantly manifested a 30-
fold reduction in their capacity to induce lethal GVHD
with no additional immunosuppression in vivo. However,
if CD4 CD25  T cells were depleted from the responder
population, the capacity of the responder cells to induce le-
thal GVHD was preserved. Thus, it appears that CD25  T
cells in the responder population are critical for the induc-
tion of tolerance in vitro. Although it remains possible that
the expression of the CD40L on the CD25  T cells may
play a role in the induction of tolerance in vitro, an alterna-
tive explanation for these results is related to the differential
requirements for costimulation for activation of the CD25 
T cells compared with CD25  T cells. CD25  suppressor
cells do not require costimulatory signals mediated by in-
teractions of CD28/CTLA-4 with CD80/CD86 (unpub-
lished observations) for induction of suppressor function,
while activation of the effectors is likely to be strongly co-
stimulation dependent. Thus, the culture conditions used
in these experiments (anti-CD40L or anti-CD80/CD86)
would favor suppression. The major consequence of
CD25 -mediated suppression is the induction of cell cycle
arrest in the CD25  responders (7) and cell cycle arrest is
normally followed by apoptotic cell death. As cell recovery
was very low in the anti-CD40L–treated cultures, it is
highly likely that tolerance in this model is secondary to
deletion. This study also raises the issue of whether some of
the therapeutic effects of anti-CD40L or anti-CD80/CD86
in other models are mediated by induction of CD25 -medi-
ated suppressor activity.
Wood’s laboratory (27) has recently described an in vivo
model that also defines a role for Tr cells, potentially de-
rived from CD4 CD25  T cells, in transplantation toler-
ance. Mice treated with a depleting anti-CD4 mAb in
combination with donor alloantigen 28 d before transplan-
tation accept donor, but not third party, grafts indefinitely.
These mice are operationally tolerant to donor alloantigens
as assessed by their ability to accept second heart or skin
grafts from the same, but not third party donors, 100 d after
transplantation. Tolerance can be adoptively transferred to
naive syngeneic recipients resulting in the prolonged sur-
vival of heart grafts from the original donor, but not a third
party. When CD4  T cells were isolated from mice ren-
dered tolerant by this protocol and fractionated into RBhigh
and RBlow populations, the capacity to mediate trans-
plantation tolerance was exclusively present in the
CD4 CD45RBlow population. Similar results were ob-
served with CD25  T cells from tolerant mice. Immune
suppression transferred by the CD45RBlow cells was medi-
ated by IL-10 and not by IL-4. The Tr cells were able to
suppress MLR’s only when the alloantigen was presented
via the indirect, but not the direct, pathway of allorecogni-
tion. Thus, the alloreactive regulatory CD4 CD45RBlow
(CD25 ) T cells identified in this study resemble in many
respects CD4 CD25  Tr cells present in normal mice. It
remains to be determined whether they are derived from
resident CD25  T cells or from CD25  cells that are stim-
ulated by alloantigen. In either case, I would propose that
Tr cells are selectively activated because alloantigen is pre-
sented under conditions where costimulation may be limit-
ing and antigen is chronically presented as donor-derived
peptides in the context of host MHC class II molecules.
The studies of Jonuleit et al. (28) implicate the immature
DCs (iDCs) as the candidate APCs involved in induction of
suppressor T cell function. When cord blood lymphocytes
were primed and repetitively stimulated with allogeneic
iDCs, they expanded poorly. Furthermore, the recovered
cells responded poorly to restimulation with mDCs, and
suppressed the responses of naive cord blood cells to stimu-F44 Commentary
lation by mDCs. Although the iDC-primed T cells pro-
duced IL-10, suppression was mediated by a cell contact–
dependent mechanism. The Tr cells expressed high levels
of CLTA-4, but Abs against CTLA-4 did not abrogate sup-
pression. The Tr cells did not downregulate the capacity of
mature DCs to stimulate and appeared to target the re-
sponder T cells. Thus, iDCs generated Tr cells have many
phenotypic and functional properties in common with
CD4 CD25  resident Tr cells. As CD4 CD25  T cells
have been identified in cord blood, it will again be impor-
tant to determine whether the regulatory cells are derived
from that population or are generated from CD25  T cells.
The Tr cells generated by stimulation with iDCs in
many respects resemble Tr1 cells (30) generated by stimula-
tion of CD4  T cells in the presence of IL-10. Although
both populations secrete IL-10 and inhibit stimulation by
alloantigen in the MLR, Tr1 cells mediate suppression in
vitro by secreting IL-10 and TGF- . One explanation for
this difference is that Groux et al. (30) used monocytes
which are sensitive to the inhibitory effects of IL-10 as the
stimulator population, whereas Jonuleit et al. (28) used
mDCs that are resistant to the inhibitory effects of IL-10.
Alternatively, differences in the culture techniques or the
starting population (cord blood versus peripheral blood) of
T cells may have resulted in the development of suppressor
cells with distinct mechanisms of suppression. In any case,
both of these studies are also consistent with the view that
Tr cells can be selectively activated under conditions where
costimulation is limiting. This unique property of Tr cells
may permit them to be activated and then suppress im-
mune responses to antigens presented by nonprofessional or
poorly activated professional APCs.
Concluding Comments. Collectively, these studies form a
solid foundation for further exploration of the role of
CD4 CD25  suppressor T cells in the regulation of both
normal and pathological immune responses. One important
theoretical question that must be addressed is the nature of
the physiologic ligand recognized by the TCR expressed
on CD25  T cells. A more practical, but equally important
question, is how to expand these cells in vitro or in vivo for
potential therapeutic purposes? Depletion of CD4 CD25 
T cells may become an important adjunct to the induction
of immunity to tumor antigens or weak vaccines.
It is highly likely that thymic-derived CD4 CD25  T
cells represent only one of potentially multiple types of reg-
ulatory/suppressor T cells. As discussed above, chronic
stimulation of CD25  T cells in vivo in the absence of co-
stimulation may result in the production of Tr cells.
Stephens and Mason (11) have described a population of
CD4 CD25  T cells that can prevent autoimmunity in the
thymectomy/irradiation model in the rat, but only if recent
CD25  thymic emigrants have been deleted from the pop-
ulation. Similarly, CD4 CD25  T cells appear to be re-
sponsible for the resistance of mice expressing a transgenic
TCR specific for myelin basic protein to the spontaneous
development of autoimmune encephalomyelitis (31). As
the expression of CD25 may not be stable, these CD25 
suppressors may have been derived from CD25  T cells.
Lastly, an intriguing possibility is that suppressors may be
generated in vivo from fully differentiated Th1 effector
cells by stimulation with antigen in the absence of costimu-
lation in a manner similar to that seen in vitro with murine
and human T cell clones (32).
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